磁共振/超声融合引导前列腺穿刺活检的学习曲线
该回顾性分析纳入2015年7月至2017年5月连续173例接受Artemis融合活检联合计算机模板系统采样的男性,评估靶向穿刺准确性与系统穿刺病理质量随时间的变化。靶向准确性在至98例时显著改善(p<0.01),系统穿刺肌纤维组织在至84例时显著减少(p<0.01),第一与第三三分位系统穿刺芯病理质量改善。
要点
- 靶向穿刺准确性在至98例时显著改善(p<0.01)。
- 系统穿刺芯肌纤维组织在至84例时显著减少(p<0.01)。
- 第一与第三三分位系统穿刺芯病理质量比较显示改善。
核心结论
- 使用Artemis平台进行靶向和系统穿刺活检存在显著学习曲线。
- 随着经验增加,靶向穿刺准确性提高且系统穿刺采样改善。
研究设计与样本
- 回顾性分析173例连续接受Artemis融合活检联合计算机模板系统采样的男性,时间为2015年7月至2017年5月。
主要发现
- 靶向穿刺准确性在至98例时显著改善(p<0.01)。
- 系统穿刺芯肌纤维组织在至84例时显著减少(p<0.01)。
- 第一与第三三分位系统穿刺芯病理质量比较显示改善。
局限性
- 使用不同融合平台可能限制结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance imaging/ultrasound-guided fusion biopsy (FBx) is more accurate at detecting clinically significant prostate cancer than conventional transrectal ultrasound-guided systematic biopsy. However, learning curves for attaining accuracy may limit the generalizability of published outcomes. OBJECTIVE: To delineate and quantify the learning curve for FBx by assessing the targeted biopsy accuracy and pathological quality of systematic biopsy over time. DESIGN, SETTING, AND PARTICIPANTS: We carried out a retrospective analysis of 173 consecutive men who underwent Artemis FBx with computer-template systematic sampling between July 2015 and May 2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The accuracy of targeted biopsy was determined by calculating the distance between planned and actual core trajectories stored on Artemis. Systematic sampling proficiency was assessed via pathological analysis of fibromuscular tissue in all cores and then comparing pathology elements from individual cores from men in the first and last tertiles. Polynomial linear regression models, change-point analysis, and piecewise linear regression were used to quantify the learning curve. RESULTS AND LIMITATION: A significant improvement in targeted biopsy accuracy occurred up to 98 cases (p<0.01). There was a significant decrease in fibromuscular tissue in the systematic biopsy cores up to 84 cases (p<0.01) and an improvement in pathological quality when comparing systematic cores from the first and third tertiles. Use of a different fusion platform may limit the generalizability of our results. CONCLUSIONS: There is a significant learning curve for targeted and systemic biopsy using the Artemis platform. Improvements in accuracy of targeted biopsy and better sampling for systematic biopsy can be achieved with greater experience. PATIENT SUMMARY: We define the learning curve for magnetic resonance imaging/ultrasound-guided fusion biopsy (FBx) using targeted biopsy accuracy and systematic core sampling quality as measures. Our findings underscore the importance of overcoming learning curves inherent to FBx to minimize patient discomfort and biopsy risk and improve the quality of care for accurate risk stratification, active surveillance, and treatment selection.
引用
- Kasabwala K, Patel N, Cricco-Lizza E, et al. The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. Eur Urol Oncol. 2018. PMID: 31017088. doi:10.1016/j.euo.2018.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。